Pulmonary arterial hypertension (PAH) is a severe and debilitating disease, with rapid disease progression and high rates of mortality. As a consequence, the necessity for effective treatments are increasingly required in order to alleviate patient symptoms and increase both quality and duration of life.

Questions Answered in This Report:

  • This report looks at how pulmonologists treat PAH, and how does treatment differs among patients of different WHO/NYHA functional classes. Which therapies do pulmonologists initiate therapy with, and what factors influence the choice of additional therapies as the disease progresses?  Are physicians willing to use off-label therapies to treat PAH, and if so, in what manner? What level of need to physicians indicate for new therapies for the treatment of PAH?

  • This report will help you understand the level of physician awareness surrounding the new therapies that are emerging for the treatment of PAH. What is the impact of the mortality/morbidity benefit on physician’s opinion of Actelion’s Opsumit? What impact will the availability of Opsumit have on the use of the other available endothelin receptor antagonists (ERAs)? How familiar are physicians with the novel mechanism of action of Bayer’s Adempas? What impact has Adempas’ approval for the treatment of CTEPH had on physicians? Are physicians aware that United Therapeutics’ Orenitram has received FDA approval? How do physicians anticipate employing Orenitram in their treatment algorithm?

  • Understand the level of satisfaction with the clinical attributes of these new agents, and how effective the sales representatives are in promoting these new therapies. How physicians rate each of the novel therapies on 18 different clinical attributes? How frequently do sales representatives meet with physicians? What message do they impart about these therapies, and how effective is this message on influencing physician opinion of these drugs?

Scope:

Sample Methodology: 45 minute online quantitative survey with several open-ended questions for qualitative feedback completed by 100 specialty pulmonologists in the U.S.

Screening Criteria: In practice between 2 and 35 years; Over 75% of time spent on patient care; Pulmonologists must treat at least 10 patients with PAH on a monthly basis; Pulmonologists must have prescribing experience of both ERAs and PDE-5 inhibitors.

Physician Research: 45 minute online quantitative survey with several open-ended questions for qualitative feedback completed by 100 US pulmonologists.

Key Drugs Covered: Opsumit, Adempas, Orenitram, Letairis, Tracleer, Revatio, Adcirca, generic sildenafil, Ventavis, Tyvaso, Flolan, Veletri, Remodulin.

Author(s): Eamonn O’Connor, Ph.D.
Ed Cortellini

Related Reports

Pulmonary Hypertension - Landscape & Forecast - Disease Landscape & Forecast

Pulmonary hypertension (PH) is a devastating disease with high levels of morbidity and mortality and no cure. Despite the disease’s rarity, the pot...

View Details

Hypertension - Unmet Need - Detailed, Expanded Analysis 2020

Primary, or essential, hypertension is defined as persistently elevated blood pressure without any identifiable cause. It is a major risk factor for various cardiovascular diseases (e.g., coronary...

View Details

Pulmonary Hypertension - Unmet Need - Detailed, Expanded Analysis ( US/EU)

PAH is a rare, life-threatening disorder marked by considerable morbidity and mortality. Despite the availability of a wide array of drugs...

View Details

Hypertension - Current Treatment - Detailed, Expanded Analysis (US)

Primary, or essential, hypertension is defined as persistently elevated blood pressure (BP) without any identifiable cause. It is a major risk factor for various...

View Details